Orphazyme A/S logo

ORPHA - Orphazyme A/S Share Price

DKK51.4 0.2  0.4%

Last Trade - 18/10/19

Sector
Healthcare
Size
Small Cap
Market Cap £118.4m
Enterprise Value £93.5m
Revenue £n/a
Position in Universe 695th / 1491
Bullish
Bearish
Unlock ORPHA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ORPHA Revenue Unlock ORPHA Revenue

Net Income

ORPHA Net Income Unlock ORPHA Revenue

Normalised EPS

ORPHA Normalised EPS Unlock ORPHA Revenue

PE Ratio Range

ORPHA PE Ratio Range Unlock ORPHA Revenue

Dividend Yield Range

ORPHA Dividend Yield Range Unlock ORPHA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ORPHA EPS Forecasts Unlock ORPHA Revenue
Profile Summary

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated June 19, 2009
Public Since November 17, 2017
No. of Shareholders: n/a
No. of Employees: 72
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 19,984,799
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address Ole Maaloees Vej 3 Copenhagen N, KOEBENHAVN, 2200, Denmark
Web https://www.orphazyme.com/
Phone +
Contact ()
Auditors Ernst & Young Godkendt Revisionspartnerselskab
ORPHA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ORPHA
Upcoming Events for ORPHA
Thursday 26th March, 2020 Estimate
Orphazyme A/S Annual Shareholders Meeting
Similar to ORPHA
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.